17α-hydroxyprogesterone caproate for the prevention of preterm birth among women at increased risk: A systematic review and meta-analysis of randomized controlled trials - 18/08/11
Abstract |
Objective |
This study was undertaken to determine whether progestational agents, initiated in the second trimester of pregnancy, reduce the risk of delivery less than 37 weeks, among women at increased risk of spontaneous preterm birth.
Study design |
Medline, pre-Medline, EMBASE, and Cochrane Central Register of Controlled Trials were searched. Randomized controlled trials with less than 20% lost to follow-up were included.
Results |
Three trials were eligible for inclusion. There was a significant reduction in risk of delivery less than 37 weeks with progestational agents (relative risk [95% CI] = 0.57 [0.36-0.90]). There was no significant effect on perinatal mortality or serious neonatal morbidity.
Conclusion |
Progestational agents, initiated in the second trimester of pregnancy, may reduce the risk of delivery less than 37 weeks' gestation, among women at increased risk of spontaneous preterm birth, but the effect on neonatal outcome is uncertain. Larger randomized controlled trials are required to determine whether this treatment reduces perinatal mortality or serious neonatal morbidity.
Le texte complet de cet article est disponible en PDF.Key words : Preterm birth, Randomized controlled trial, Progestational agent, Systematic review
Plan
| Reprints not available from the authors. |
Vol 194 - N° 5
P. 1234-1242 - mai 2006 Retour au numéro
Article précédent
- Is vitamin E a safe prophylaxis for preeclampsia?
- Subhasis Banerjee, Anne E. Chambers, Stuart Campbell
- External anal sphincter volume measurements using 3-dimensional endoanal ultrasound
- W. Thomas Gregory, Sarah Hamilton Boyles, Kimberly Simmons, Amy Corcoran, Amanda L. Clark
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?